Search

everythinglearnresearchcommunity

for

Search:↓

Early signs of PCOS in girls, like irregular periods and polycystic ovaries, suggest a need for early diagnosis and intervention to prevent further health issues.

Metformin improves early signs of heart disease in women with PCOS and raises apelin levels, but doesn't significantly change artery thickness.

PCOS is a hormonal issue in women that is usually treated with birth control pills, metformin, and lifestyle changes, with early treatment helping to reduce complications and improve life quality.

The 2003 consensus updated PCOS diagnosis criteria and highlighted increased risks of diabetes and heart disease for those affected.

Women with PCOS should be screened for heart disease risk and manage their health to prevent it.

Metformin helps with menstrual cycles and insulin levels in PCOS but is less effective for hair growth, diabetes prevention, and weight loss, and may improve fertility and reduce diabetes risk.

Insulin resistance and obesity are key factors in the development and worsening of polycystic ovary syndrome, and lifestyle changes are important for managing it.

High levels of male hormones, insulin resistance, and obesity are closely linked and worsen polycystic ovary syndrome, but more research is needed to improve treatments.

The conclusion is that PCOS is caused by ovarian sensitivity to hormones and disrupted hormone control, possibly due to ovarian factors, and more research is needed.

Diffuse alopecia in women may be related to androgens and iron deficiency, and basic hormone and nutrient screening is useful.

Women with PCOS and higher androgen levels are more likely to have fatty liver disease.

People with PCOS, especially if obese, often have NAFLD, linked to obesity, insulin resistance, and high androgen levels.

Flutamide may slightly improve hair loss in women, but finasteride does not work.

Too much male hormone is the main cause of Polycystic Ovary Syndrome.

The document concludes that hirsutism is the main sign for diagnosing hyperandrogenism, which requires a detailed patient history and physical exam.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

Women with PCOS have higher androgen levels that decrease with age but are still higher than in women without PCOS.

Insulin resistance may contribute to various skin diseases and treating it could improve skin health and prevent more serious conditions.

Low SHBG and high FAI, FT, and DHEAS levels are effective in identifying PCOS.

Insulin resistance contributes to hormone imbalances in many women with polycystic ovary syndrome.

About 13% of women had idiopathic hirsutism and 8.5% had polycystic ovary syndrome in a group of Iranian women.

Hormonal therapies are safe and effective for treating adult women's acne.

The conclusion is that oral contraceptives and antiandrogens can treat hirsutism and acne in women with cutaneous hyperandrogenism, but more research is needed for effective treatments, especially for hair loss.

Insulin-lowering medications show promise for PCOS symptoms but can't be the main treatment yet due to limited long-term research.

The document suggests that clinical trials for PCOS should focus on meaningful primary outcomes like live birth rates, rather than less reliable surrogate markers.

The conclusion is that accurately identifying the cause of high androgen levels in women with PCOS is crucial and requires specific tests.

New treatments for PCOS focus on insulin resistance and reducing testosterone levels, along with traditional hormone therapies.

Girls with PCOS during adolescence have a higher risk of developing type 2 diabetes, and early treatment can help manage this risk.

Antiandrogens have important biological effects, but more research is needed to understand them fully and compare their effectiveness and side effects to other treatments.

The document concludes that proper diagnosis and combined treatments are key for hirsutism management, and weight loss may help overweight patients.